KR20220091490A - Pd1 및 vegfr2 이중 결합제 - Google Patents
Pd1 및 vegfr2 이중 결합제 Download PDFInfo
- Publication number
- KR20220091490A KR20220091490A KR1020227014433A KR20227014433A KR20220091490A KR 20220091490 A KR20220091490 A KR 20220091490A KR 1020227014433 A KR1020227014433 A KR 1020227014433A KR 20227014433 A KR20227014433 A KR 20227014433A KR 20220091490 A KR20220091490 A KR 20220091490A
- Authority
- KR
- South Korea
- Prior art keywords
- seq
- amino acid
- acid sequence
- ser
- sequence comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1914747.9 | 2019-10-11 | ||
| GB201914747A GB201914747D0 (en) | 2019-10-11 | 2019-10-11 | PD1 and vegfr2 dual-binding agents |
| GBGB2013180.1A GB202013180D0 (en) | 2019-10-11 | 2020-08-24 | Pd1 and vegfr2 dual-binding agents |
| GB2013180.1 | 2020-08-24 | ||
| PCT/EP2020/078427 WO2021069670A1 (en) | 2019-10-11 | 2020-10-09 | Pd1 and vegfr2 dual-binding agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20220091490A true KR20220091490A (ko) | 2022-06-30 |
Family
ID=68619556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020227014433A Pending KR20220091490A (ko) | 2019-10-11 | 2020-10-09 | Pd1 및 vegfr2 이중 결합제 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US20240101674A1 (https=) |
| EP (3) | EP4041763B1 (https=) |
| JP (2) | JP7689116B2 (https=) |
| KR (1) | KR20220091490A (https=) |
| CN (2) | CN114981301B (https=) |
| AU (1) | AU2020365021A1 (https=) |
| CA (2) | CA3289307A1 (https=) |
| DK (1) | DK4041763T3 (https=) |
| ES (1) | ES3027238T3 (https=) |
| FI (1) | FI4041763T3 (https=) |
| GB (2) | GB201914747D0 (https=) |
| HR (1) | HRP20250523T1 (https=) |
| HU (1) | HUE071341T2 (https=) |
| IL (1) | IL292158A (https=) |
| LT (1) | LT4041763T (https=) |
| PL (1) | PL4041763T3 (https=) |
| PT (1) | PT4041763T (https=) |
| RS (1) | RS66837B1 (https=) |
| SI (1) | SI4041763T1 (https=) |
| WO (1) | WO2021069670A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109053895B (zh) | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
| CN116143935A (zh) * | 2021-11-22 | 2023-05-23 | 杭州翰思生物医药有限公司 | 重组抗体及其应用 |
| WO2024032662A1 (zh) * | 2022-08-09 | 2024-02-15 | 上海济煜医药科技有限公司 | 一种靶向pd-1和vegf的抗体及其应用 |
| CN118620082A (zh) * | 2023-03-10 | 2024-09-10 | 南京维立志博生物科技有限公司 | 靶向vegf途径和pd-1的双特异性抗原结合蛋白、其组合物和用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| RU2689760C2 (ru) * | 2012-05-31 | 2019-05-30 | Дженентек, Инк. | Способы лечения рака с применением антагонистов аксиального связывания pd-1 и vegf антагонистов |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| SG10201804945WA (en) * | 2013-12-12 | 2018-07-30 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
| WO2017055404A1 (en) | 2015-10-02 | 2017-04-06 | F. Hoffmann-La Roche Ag | Bispecific antibodies specific for pd1 and tim3 |
| CN109893654B (zh) * | 2017-12-11 | 2021-07-27 | 江苏恒瑞医药股份有限公司 | Vegfr抑制剂治疗肿瘤的方法 |
| GB201803746D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| GB201803745D0 (en) | 2018-03-08 | 2018-04-25 | Ultrahuman Eight Ltd | PD1 binding agents |
| CN109053895B (zh) * | 2018-08-30 | 2020-06-09 | 中山康方生物医药有限公司 | 抗pd-1-抗vegfa的双功能抗体、其药物组合物及其用途 |
| TWI822897B (zh) | 2018-11-06 | 2023-11-21 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 |
| GB201914747D0 (en) | 2019-10-11 | 2019-11-27 | Ultrahuman Eight Ltd | PD1 and vegfr2 dual-binding agents |
-
2019
- 2019-10-11 GB GB201914747A patent/GB201914747D0/en not_active Ceased
-
2020
- 2020-08-24 GB GBGB2013180.1A patent/GB202013180D0/en not_active Ceased
- 2020-10-09 LT LTEPPCT/EP2020/078427T patent/LT4041763T/lt unknown
- 2020-10-09 DK DK20789105.2T patent/DK4041763T3/da active
- 2020-10-09 SI SI202030611T patent/SI4041763T1/sl unknown
- 2020-10-09 HR HRP20250523TT patent/HRP20250523T1/hr unknown
- 2020-10-09 CN CN202080075802.2A patent/CN114981301B/zh active Active
- 2020-10-09 CN CN202511932691.3A patent/CN121758618A/zh active Pending
- 2020-10-09 AU AU2020365021A patent/AU2020365021A1/en active Pending
- 2020-10-09 US US17/768,013 patent/US20240101674A1/en active Pending
- 2020-10-09 CA CA3289307A patent/CA3289307A1/en active Pending
- 2020-10-09 PL PL20789105.2T patent/PL4041763T3/pl unknown
- 2020-10-09 HU HUE20789105A patent/HUE071341T2/hu unknown
- 2020-10-09 EP EP20789105.2A patent/EP4041763B1/en active Active
- 2020-10-09 WO PCT/EP2020/078427 patent/WO2021069670A1/en not_active Ceased
- 2020-10-09 JP JP2022521074A patent/JP7689116B2/ja active Active
- 2020-10-09 EP EP25159487.5A patent/EP4570824A3/en active Pending
- 2020-10-09 ES ES20789105T patent/ES3027238T3/es active Active
- 2020-10-09 KR KR1020227014433A patent/KR20220091490A/ko active Pending
- 2020-10-09 PT PT207891052T patent/PT4041763T/pt unknown
- 2020-10-09 CA CA3156096A patent/CA3156096C/en active Active
- 2020-10-09 FI FIEP20789105.2T patent/FI4041763T3/fi active
- 2020-10-09 RS RS20250448A patent/RS66837B1/sr unknown
- 2020-10-09 EP EP25212556.2A patent/EP4671279A2/en active Pending
-
2022
- 2022-04-11 IL IL292158A patent/IL292158A/en unknown
-
2025
- 2025-02-18 US US19/056,312 patent/US12479920B2/en active Active
- 2025-05-26 JP JP2025087525A patent/JP2025134713A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PT4041763T (pt) | 2025-05-16 |
| EP4570824A2 (en) | 2025-06-18 |
| EP4671279A2 (en) | 2025-12-31 |
| EP4570824A3 (en) | 2025-06-25 |
| CN121758618A (zh) | 2026-03-31 |
| DK4041763T3 (da) | 2025-05-19 |
| RS66837B1 (sr) | 2025-06-30 |
| US20250243276A1 (en) | 2025-07-31 |
| AU2020365021A1 (en) | 2022-05-26 |
| JP7689116B2 (ja) | 2025-06-05 |
| US12479920B2 (en) | 2025-11-25 |
| SI4041763T1 (sl) | 2025-08-29 |
| WO2021069670A1 (en) | 2021-04-15 |
| CN114981301A (zh) | 2022-08-30 |
| CA3289307A1 (en) | 2026-03-02 |
| EP4041763B1 (en) | 2025-02-26 |
| HUE071341T2 (hu) | 2025-08-28 |
| JP2025134713A (ja) | 2025-09-17 |
| HRP20250523T1 (hr) | 2025-07-04 |
| EP4041763A1 (en) | 2022-08-17 |
| GB201914747D0 (en) | 2019-11-27 |
| ES3027238T3 (en) | 2025-06-13 |
| GB202013180D0 (en) | 2020-10-07 |
| LT4041763T (lt) | 2025-06-10 |
| CA3156096A1 (en) | 2021-04-15 |
| IL292158A (en) | 2022-06-01 |
| FI4041763T3 (fi) | 2025-05-15 |
| US20240101674A1 (en) | 2024-03-28 |
| PL4041763T3 (pl) | 2025-07-07 |
| JP2022553908A (ja) | 2022-12-27 |
| CN114981301B (zh) | 2026-04-14 |
| CA3156096C (en) | 2026-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111683970B (zh) | C-kit结合剂 | |
| US10858435B2 (en) | PD1 binding agents | |
| JP7689116B2 (ja) | Ｐｄ１およびｖｅｇｆｒ２二重結合剤 | |
| US12415861B2 (en) | Anti C-MET antibodies | |
| CN111819201A (zh) | Pd1结合剂 | |
| CN111818972A (zh) | 去免疫的抗erbb3抗体 | |
| US11655300B2 (en) | Colony stimulating factor 1 receptor (CSF1R) antibodies and immunoconjugates thereof | |
| HK40075900A (en) | Pd1 and vegfr2 dual-binding agents | |
| HK40075900B (en) | Pd1 and vegfr2 dual-binding agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |